Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
Aim: To evaluate the cost utility and budget impact of second-line gefitinib for non-small cell lung cancer from a Thai payer perspective. Methods: A Markov model with three health states (pre-progression, post-progression and death) was constructed to estimate direct medical costs and outcomes co...
Saved in:
Main Authors: | Thongprasert S., Tinmanee S., Permsuwan U. |
---|---|
Format: | Article |
Language: | English |
Published: |
2014
|
Online Access: | http://www.ncbi.nlm.nih.gov/pubmed/3502482 http://cmuir.cmu.ac.th/handle/6653943832/4573 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Language: | English |
Similar Items
-
Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
by: Thongprasert,S., et al.
Published: (2015) -
Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand
by: Unchalee Permsuwan, et al.
Published: (2020) -
Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
by: Thongprasert S., et al.
Published: (2017) -
Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer
by: Thongprasert S., et al.
Published: (2014) -
Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
by: Sumitra Thongprasert, et al.
Published: (2018)